Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. 1995

F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
Unité des papillomavirus, Institut National de la Santé et de la Recherche Médicale U-190, Institut Pasteur, Paris, France.

We tested the ability of vaccination with virus-like particles (VLPs) to protect domestic rabbits against papillomas induced by the cottontail rabbit papillomavirus (CRPV). A recombinant baculovirus system that expressed only the L1 major papillomavirus structural protein or L1 plus the minor L2 protein was used in insect cells as the source of VLPs. Groups of 10 rabbits were immunized with native or denatured VLPs from CRPV or type 1 bovine papillomavirus by using Freund's adjuvant. Alum was used as the adjuvant for an additional group immunized with CRPV L1-L2 VLPs. Animals were challenged with 5 x 10(10) and 2 x 10(11) particles on opposing flanks. No protection was seen in rabbits immunized with native or denatured bovine papillomavirus L1-L2 or with denatured CRPV L1-L2. In these groups, the lower and higher challenge doses resulted in 27 of 30 animals with extensive papillomas, with each of the remaining animals having a smaller number of persistent papillomas. Progression to carcinoma developed in 20 rabbits. Animals inoculated with native CRPV VLPs composed of L1 alone or L1-L2 developed many fewer lesions; the lower and higher challenge doses resulted in 17 of 29 and 5 of 29 rabbits, respectively, with no lesions, and the remainder developed only one to eight papillomas, which all regressed except for those on 1 rabbit. None developed cancer within 1 year of infection. Rabbits vaccinated with native CRPV VLPs developed high-titer antibodies in an enzyme-linked immunosorbent assay based on native VLPs, and passive transfer of serum or immunoglobulin G from rabbits immunized with CRPV VLPs protected against CRPV challenge. We conclude that native VLPs can induce antibody-mediated, type-specific protection against experimental papillomavirus infection.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D001769 Blood The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012777 Cottontail rabbit papillomavirus The type species of KAPPAPAPILLOMAVIRUS. It is reported to occur naturally in cottontail rabbits in North America. Papilloma Virus, Shope,Papillomavirus sylvilagi,Shope Papilloma Virus,Cottontail rabbit papillomaviruses,papillomaviruses, Cottontail rabbit
D014412 Tumor Virus Infections Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses. Fibroma, Shope,Papilloma, Shope,Infections, Tumor Virus,Infection, Tumor Virus,Shope Fibroma,Shope Papilloma,Tumor Virus Infection
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014765 Viral Vaccines Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. Viral Vaccine,Vaccine, Viral,Vaccines, Viral

Related Publications

F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
February 1996, Journal of virology,
F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
November 1995, Vaccine,
F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
March 2006, Vaccine,
F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
January 1997, Vaccine,
F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
February 2008, Vaccine,
F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
March 2008, Virology journal,
F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
January 2005, Antiviral chemistry & chemotherapy,
F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
October 2013, Journal of wildlife diseases,
F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
July 2007, Virus research,
F Breitburd, and R Kirnbauer, and N L Hubbert, and B Nonnenmacher, and C Trin-Dinh-Desmarquet, and G Orth, and J T Schiller, and D R Lowy
April 1992, Virology,
Copied contents to your clipboard!